(Q33356674)

26 July 2017

title

Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors (English)

1 reference

26 July 2017

9

Mercedes Armand-Ugón

0 references

Imma Clotet-Codina

8

Imma Clotet-Codina

1 reference

Raimon Puig de La Bellacasa

26 July 2017

Raimon Puig de La Bellacasa

4

0 references

Obdulia Rabal

María Obdulia Rabal

5

0 references

José I Borrell

José I Borrell

11

0 references

Jordi Teixidó

Jordi Teixidó

12

0 references

José A. Esté

José Esté

10

0 references

Bonaventura Clotet Sala

7

Bonaventura Clotet

1 reference

26 July 2017

Sofia Pettersson

1

1 reference

26 July 2017

Violeta I Pérez-Nueno

2

1 reference

26 July 2017

Laia Ros-Blanco

3

1 reference

26 July 2017

Xavier Batllori

6

1 reference

26 July 2017

publication date

1 October 2008

1 reference

26 July 2017

1 reference

26 July 2017

volume

3

1 reference

26 July 2017

issue

10

1 reference

26 July 2017

page(s)

1549-1557

1 reference

Virus entry as a target for anti-HIV intervention

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

HIV entry inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

HIV-1 integrase: a target for new AIDS chemotherapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

HIV-1 reverse transcriptase inhibitors: current issues and future perspectives

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Nevirapine in the treatment of HIV.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Anti-HIV drug development--an overview

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Structure and function of HIV-1 integrase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Design and development of integrase inhibitors as anti-HIV agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

HIV-1 integrase inhibition: binding sites, structure activity relationships and future perspectives.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Human cell proteins and human immunodeficiency virus DNA integration

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Novel inhibitors of HIV-1 integration.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Inhibitors of HIV-1 gene expression and transcription

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

The HIV-1 Nef protein: how an AIDS pathogenetic factor turns to a tool for combating AIDS.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200800145

1 reference

7 January 2021

HIV-1 assembly and maturation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200800145

1 reference

7 January 2021

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Discovery of small molecule CXCR4 antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Analysis of selection methodologies for combinatorial library design

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Recent advances in combinatorial chemistry applied to development of anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Comparative protein modelling by satisfaction of spatial restraints

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Comparison of ligand-based and receptor-based virtual screening of HIV entry inhibitors for the CXCR4 and CCR5 receptors using 3D ligand shape matching and ligand-receptor docking

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Comparative analysis of putative agonist-binding modes in the human A1 adenosine receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Molecular dynamics simulations on SDF-1alpha: binding with CXCR4 receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800145

7 January 2021

Identifiers

DOI

10.1002/CMDC.200800145

1 reference

26 July 2017

1 reference